The identification of novel targets for chronic myeloid leukemia is of interest.
BCR-ABL1 inhibition reduces AURKA and AURKB expression.
Reversine is an AURKA and AURKB inhibitor.
Reversine leads to increased apoptosis and mitotic catastrophe in K562 cells.
Reversine exibits antileukemic activity against K562 cells.